BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed breast cancer
• Metastatic disease by radiography or histology
• Must have received prior chemotherapy with a taxane and an anthracycline in the adjuvant or metastatic setting
• No more than 2 prior chemotherapy regimens in the metastatic setting
• Measurable or evaluable disease
• Bone lesions not measurable
• Primary breast lesions not measurable if assessed only by physical exam
• No active brain metastasis
• No cerebral edema by CT scan or MRI
• No progression since prior imaging studies
• No requirement for steroids
• No clinical symptoms of brain metastasis
• Hormone receptor status:
• Not specified

PATIENT CHARACTERISTICS:

Age

• 18 and over

Sex

• Not specified

Menopausal status

• Not specified

Performance status

• ECOG 0-1

Life expectancy

• At least 3 months

Hematopoietic

• Absolute neutrophil count at least 2,000/mm^3
• Platelet count at least 100,000/mm^3
• Hemoglobin at least 9.0 g/dL

Hepatic

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• ALT no greater than 2.5 times ULN

Renal

• Creatinine less than 1.5 times ULN

Cardiovascular

• No uncontrolled or significant cardiovascular disease
• No myocardial infarction within the past year
• No uncontrolled angina within the past year
• No history of congestive heart failure
• No history of atrial or ventricular arrhythmias
• No history of second- or third-degree heart block
• No uncontrolled hypertension

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No hypersensitivity to Cremophor EL or fluorouracil
• No prior intolerance to fluoropyrimidines
• No other serious uncontrolled medical disorder or active infection that would preclude study
• No dementia or altered mental status that would preclude study
• No grade 2 or greater neuropathy (neuromotor or neurosensory)

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Chemotherapy
• Prior immunotherapy allowed
• No concurrent trastuzumab (Herceptin)
• No concurrent immunotherapy

Chemotherapy

• See Disease Characteristics
• At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or doxorubicin HCl liposome)
• At least 2 years since prior high-dose chemotherapy with bone marrow transplantation or peripheral blood stem cell support
• No prior epothilone, capecitabine, or continuous-infusion fluorouracil
• No other concurrent chemotherapy

Endocrine therapy

• Prior hormonal therapy allowed
• No concurrent hormonal therapy
• Concurrent hormone replacement therapy allowed

Radiotherapy

• At least 3 weeks since prior radiotherapy
• No prior radiotherapy to more than 25% of the bone marrow
• No concurrent therapeutic radiotherapy

Surgery

• Not specified

Other

• At least 3 weeks since prior investigational cytotoxic agents
• No concurrent warfarin for therapeutic anticoagulation
• Low-dose warfarin allowed for implanted ports or indwelling catheters
• No other concurrent experimental anticancer medications
• No other concurrent antitumor therapy
• Concurrent bisphosphonates for palliation of bone metastases allowed if initiated before study